HIF-1alpha vs HIF-2alpha: Related but Distinct Hypoxia Factors

A Shared Regulatory Mechanism

Both HIF-1alpha and HIF-2alpha (encoded by EPAS1) partner with HIF-1beta and, in normal oxygen, are marked for destruction. Prolyl hydroxylases add hydroxyl groups that let the VHL protein target them for degradation.

When oxygen is low, or when VHL is lost, the alpha subunits are stabilised, enter the nucleus and activate hypoxia-response genes.

Different Target Genes and Timing

HIF-1alpha strongly drives genes for glycolysis and acute metabolic adaptation and tends to dominate the early response to hypoxia. HIF-2alpha more strongly drives VEGFA, erythropoietin, and genes linked to stemness and invasion, and tends to sustain signalling during chronic hypoxia.

The two can also have opposing effects on some targets, including MYC activity, so they are not simply redundant.

Tissue and Tumour Context

HIF-2alpha expression is more restricted, prominent in endothelium, kidney interstitial cells, hepatocytes and some other tissues. In clear cell renal cell carcinoma, VHL loss is near-universal and HIF-2alpha is the key oncogenic driver, whereas HIF-1alpha can act as a tumour suppressor in that specific cancer.

In many other tumour types HIF-1alpha is the more prominent pro-tumour factor, so the balance is context-dependent.

HIF-2alpha as a Drug Target

Belzutifan is a small-molecule HIF-2alpha inhibitor that blocks its dimerisation with HIF-1beta. It is approved for VHL-disease-associated renal cell carcinoma and certain other VHL-associated tumours, and for some patients with advanced sporadic clear cell renal cell carcinoma.

Anaemia and hypoxia are on-target effects, reflecting HIF-2alpha's normal role in erythropoietin production.

Interpretation Notes

Germline EPAS1 (HIF-2alpha) gain-of-function variants cause rare syndromes with paraganglioma, polycythaemia and somatostatinoma, which is a distinct context from sporadic tumour hypoxia signalling.

HIF immunostaining or signatures in a tumour report describe pathway activity and are not standalone predictive tests outside the specific renal cancer setting.

Key Takeaways

• ·HIF-1alpha and HIF-2alpha share VHL-dependent regulation but activate different gene sets.
• ·HIF-1alpha favours acute glycolytic adaptation; HIF-2alpha favours VEGFA, erythropoietin and chronic responses.
• ·In clear cell renal cell carcinoma HIF-2alpha is the oncogenic driver and belzutifan targets it.
• ·The pro-tumour balance between the two is tissue-specific.